Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women

This study has been completed.
Sponsor:
Collaborator:
KGK Synergize Inc.
Information provided by:
Mondelēz International, Inc.
ClinicalTrials.gov Identifier:
NCT00931034
First received: June 29, 2009
Last updated: June 30, 2009
Last verified: June 2009

June 29, 2009
June 30, 2009
March 2007
April 2008   (final data collection date for primary outcome measure)
Change in body weight from baseline to week 24 [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00931034 on ClinicalTrials.gov Archive Site
  • Assess the satiety response to the individual diets [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Analyze circumference measurements & body composition; blood glucose, HbA1c, insulin, lipid profile, blood pressure & questionnaire responses on food cravings and quality of life [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women
The Effect of South Beach Diet™ Using South Beach Diet™ Products Compared to the American Diabetic Association Diabetes Meal Plan on Body Weight and Satiety in Overweight Diabetic Women

The purpose of this study is to examine the effectiveness of the South Beach Diet and products compared to the American Diabetic Association Diabetes Meal Plan.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Behavioral: South Beach Diet with South Beach Diet Products
  • Behavioral: American Diabetes Association Diabetes Meal Plan
  • Active Comparator: South Beach Diet with SBD Products
    Intervention: Behavioral: South Beach Diet with South Beach Diet Products
  • Active Comparator: ADA Diabetes meal plan
    Intervention: Behavioral: American Diabetes Association Diabetes Meal Plan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
July 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Female age 18 to 55 years
  2. Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result
  3. Healthy as determined by laboratory results and medical history
  4. Waist circumference > 87 cm
  5. Stable weight defined as < 4.5 kg gained or lost in past year
  6. Agreement to maintain current level of physical activity throughout the study
  7. Diagnosed with Type II diabetes mellitus with fasting blood glucose 100 - 250 mg/dl (5.6 - 13.9 mmol/L)
  8. Ability to comprehend and complete the questionnaires and forms
  9. Agreement to comply with study procedures, test article consumption, and has access to a microwave oven
  10. Voluntary, written, informed consent to participate in the study

Exclusion Criteria:

  1. Pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  2. Use of prescription or over the counter products known to effect weight including but not limited to the following:

    • megestrol acetate;
    • somatropin;
    • sibutramine;
    • orlistat;
    • paroxetine;
    • dextroamphetamine;
    • methylphenidate;
    • atomoxetine;
    • quetiapine;
    • olanzepine;
    • risperidone, within 4 weeks of randomization and during the trial
  3. Unstable medication for diabetes mellitus (Dosage must be stable for 90 days prior to randomization), use of insulin is exclusionary
  4. Alcohol use > 2 standard alcoholic drinks per day
  5. Significant cardiac history defined as a history of:

    • myocardial infarction (MI);
    • coronary angioplasty or bypass graft(s);
    • valvular disease or repair;
    • unstable angina pectoris;
    • transient ischemic attack (TIA);
    • cerebrovascular accidents (CVA);
    • congestive heart failure; or
    • coronary artery disease (CAD)
  6. History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission for more than 5 years are acceptable.
  7. Uncontrolled hypertension defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg
  8. Unstable renal and/or liver disease
  9. History of alcohol or drug abuse within the past year
  10. Unstable psychiatric disorder requiring hospitalization within the past 6 months
  11. Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
  12. History of hemoglobinopathies such as sickle cell anemia or thalassemia, sideroblastic anemia
  13. Participation in another clinical research trial within 30 days prior to randomization and during the trial
  14. Significant abnormal liver function as defined as AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN
  15. Serum creatinine > 125 umol/L
  16. Anemia of any etiology defined as hemoglobin < 110 g/L
  17. Uncontrolled and/or untreated thyroid disorder
  18. Unstable medications (Dosage must be stable for 90 days prior to randomization)
  19. History of food allergies or sensitivities, including lactose intolerance
  20. Vegetarians
  21. Cognitively impaired and/or unable to give informed consent
  22. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
Female
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00931034
07SWHK
No
Richard Black, PhD/VP, Nutrition, Kraft Foods
Mondelēz International, Inc.
KGK Synergize Inc.
Study Director: David Crowley, MD KGK Synergize Inc.
Mondelēz International, Inc.
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP